Table 1 Baseline characteristics of patients participating in RA-BEGIN [22], RA-BEAM [10] and RA-BUILD [9]
Characteristic | RA-BEGIN (csDMARD- and bDMARD-naïve) | RA-BEAM (MTX-inadequate responders and bDMARD-naïve) | RA-BUILD (csDMARD-inadequate responders and bDMARD-naïve) | ||||||
|---|---|---|---|---|---|---|---|---|---|
MTX once weekly (N = 210) | Baricitinib 4 mg QD (N = 159) | Baricitinib 4 mg + MTX (N = 215) | Placebo (N = 488) | Baricitinib 4 mg QD + background MTX (N = 487) | Adalimumab 40 mg Q2W + background MTX (N = 330) | Placebo (N = 228) | Baricitinib 2 mg QD (N = 229) | Baricitinib 4 mg QD (N = 227) | |
Age, years | 51 ± 13 | 51 ± 13 | 49 ± 14 | 53 ± 2 | 54 ± 2 | 53 ± 12 | 51 ± 13 | 52 ± 12 | 52 ± 12 |
Female, n (%) | 148 (70) | 121 (76) | 156 (73) | 382 (78) | 375 (77) | 251 (76) | 189 (83) | 184 (80) | 187 (82) |
Duration of RA, years | 1 ± 4 | 2 ± 5 | 1 ± 3 | 10 ± 9 | 10 ± 9 | 10 ± 9 | 7 ± 8 | 8 ± 8 | 8 ± 8 |
≥ 1 erosion, n (%) | 138 (66) | 105 (66) | 137 (64) | 371 (76) a | 371 (76)a | 245 (75)a,b | 170 (75) | 163 (71) | 169 (75) |
ACPA positive, n (%)c | 193 (92) | 142 (89) | 192 (89) | 424 (87) | 427 (88) | 295 (89) | 172 (75) | 169 (74) | 163 (72) |
RF positive, n (%)d | 203 (97) | 155 (97) | 204 (95) | 451 (92) | 439 (90) | 301 (91) | 171 (75) | 177 (77) | 173 (76) |
ACPA and RF positive, n (%) | 192 (92) | 139 (87) | 186 (87) | 415 (85) | 407 (84) | 280 (85) | 157 (69) | 161 (70) | 152 (67) |
hsCRP level, mg/Le | 22 ± 22 | 24 ± 26 | 24 ± 29 | 20 ± 21 | 22 ± 23 | 22 ± 21 | 18 ± 20 | 18 ± 22 | 14 ± 15 |
mTSS units | 12 ± 22 | 13 ± 27 | 11 ± 20 | 45 ± 50 | 43 ± 50 | 44 ± 51 | 19 ± 31 | 26 ± 40 | 24 ± 40 |
Erosion score | 8 ± 13 | 9 ± 16 | 8 ± 12 | 27 ± 29 | 25 ± 28 | 26 ± 29 | 12 ± 19 | 16 ± 24 | 15 ± 23 |
Joint space narrowing score | 4 ± 10 | 5 ± 12 | 4 ± 10 | 18 ± 23 | 17 ± 23 | 18 ± 24 | 7 ± 14 | 10 ± 18 | 9 ± 18 |